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Abstract
Stroke induces not only cell death but also neurorepair. De novo neurogenesis has been found in the subventricular zone of
the adult mammalian brain days after stroke. Most of these newly generated cells die shortly after the insult. Recent studies
have shown that pharmacological manipulation can improve the survival of endogenous neuroprogenitor cells and neural
regeneration in stroke rats. As these drugs target the endogenous reparative processes that occur days after stroke, they may
provide a prolonged window for stroke therapy. Here, we discuss endogenous neurogenesis-enhancing drugs and review the
general status of stroke therapeutics in evaluating the field of pharmacotherapy for stroke.
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Introduction
After the onset of ischemic brain injury, a series of timedependent pathophysiological responses are activated. These
reactions not only include excitotoxicity, apoptosis, leakage
of the blood–brain barrier (BBB), and inflammation cell death
but also endogenous neural repair (for details, please see the
study by Brouns and De Deyn1). Some of these responses
occur shortly after stroke and last for hours up to 1 to 2 d.
One example is the apoptotic cascades at the ischemic site.2
Using a rodent distal middle cerebral artery occlusion
(MCAo) model, it has been demonstrated that the density of
terminal deoxynucleotidyl transferase 20 -deoxyuridine 50 -triphosphate (dUTP) nick end labeling (TUNEL) labeling in the
ischemic cortex peaks on day 2 and returns to basal levels
within 6 d after MCAo.3 Similarly, p53 messenger RNA
(mRNA) or protein is upregulated shortly after stroke, which
leads to p53-dependent programmed cell death in the penumbra.4,5 Because of the short duration of apoptosis/necrosis in
the ischemic region, the efficacy of pharmacological treatment to reduce this mechanism is often restricted by its narrow therapeutic window. Stroke animals receiving p53
inhibitor treatment, given before or shortly after MCAo, had
less brain infarction.6,7 P53 inhibitors given 3 h or later had no
beneficial effect on neuronal cell loss7 and did not alter locomotor behaviors.3 Taken together, these data suggest that the
suppression of apoptosis in the ischemic-lesioned region must

take place early after MCAo. This temporal restriction has
limited the clinical potential for these drugs.
Cerebral ischemia also activates delayed endogenous
repair processes. De novo neurogenesis was found in the
subventricular zone (SVZ) of adult mammalian brain days
after stroke.8 The kinetics of neural progenitor cells (NPCs)
in the SVZ following ischemia has been examined using
bromodeoxyuridine (BrdU) labeling.3 A robust increase in
BrdU immunoreactivity in the SVZ occurred as early as 2
days after distal MCAo. The increase in BrdU immunoreactivity was sustained through 4 days after MCAo, started to
decline between days 6 and 8, and returned to basal levels
about day 10. These data suggest differential temporal windows of cell proliferation in the SVZ and cell death in the
ischemic-lesioned zone. Targeting the survival of the
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endogenous NPCs in SVZ may enable a longer treatment
window after the onset of stroke.3,9

Endogenous Neurogenesis-Enhancing Drugs
Several candidate chemicals were recently developed to
modulate survival, proliferation, migration, or differentiation of NPCs in the SVZ. Since these drugs aim at the endogenous reparative processes, which occur days after stroke,
they may provide a prolonged window for stroke therapy.
The following are examples of these drugs that may be
potentially used for the delayed stroke therapy.
A.

B.

Pifithrin-a (PFT-a): Although stroke can activate the
proliferation of NPCs in the SVZ, most of these cells
die after injury.10 The NPCs in the SVZ express high
levels of p53 protein.11 Increased TUNEL activity
was found in the SVZ of stroke rats,3 indicating that
apoptosis is also involved in the death of these
NPCs. As the activation of NPC proliferation in SVZ
occurs at a later stage,12 administration of PFT-a, a
p53 inhibitor, starting from day 6 after MCAo, was
found to enhance the survival of endogenous NPCs
in the SVZ and improve motor function in stroke
rats.3 These data suggest that inhibition of p53 may
extend the survival of endogenous NPCs and alter
biological outcomes days after stroke.
Trophic factors: Selective trophic factors have been
shown to enhance neuroreparative activity after
stroke. For example:
i. Bone morphogenetic protein 7 (BMP7). BMP7 is a
trophic protein in the transforming growth factor-b
(TGF-b) superfamily. BMP7 can promote DNA
synthesis, as visualized by BrdU incorporation in
mesencephalic-cultured neurons.13 Posttreatment
with BMP7 enhanced the recovery of sensorimotor
function in the impaired limbs,14,15 decreased body
asymmetry, and increased locomotor activity from
day 7 to day 14 after MCAo.16 BMP7 also
increased BrdU immunoreactivity in the SVZ,
lesioned cortex, and corpus callosum. The BrdUpositive cells were co-labeled with nestin and
NeuN.17 These data support that BMP7 improves
functional recovery through the proliferation of
new neuronal precursors in the stroke brain.
ii. Brain-derived neurotrophic factor (BDNF). In
nonstroke animals, BDNF has been shown to
enhance migration of NPCs from the SVZ
toward the olfactory bulbs.18-20 In stroke animals, systemic administration of BDNF
enhanced the recruitment of NPCs into the
lesioned site.21 Atorvastatin, a chemical that
activates the expression of BDNF, enhanced
migration of SVZ cells.9,22 Similarly, overexpression of BDNF through gene therapy via
Adeno-associated virus (AAV) infection

facilitated endogenous NPC migration from the
SVZ and improved the functional recovery.23
These data suggest that administration of BDNF
protein or increasing BDNF expression facilitates
behavioral recovery through the enhancement
of migration of NPCs from the SVZ in stroke
animals.
iii. Other trophic factors: Several other trophic factors
have also been reported to induce neurorepair in
experimental stroke animals. For example, transplantation of neural stem cells or human umbilical
cord blood CD34þ cells overexpressing glial cell
line derived neurotrophic factor (GDNF)enhanced neurogenesis.24,25 Infusion of GDNF
increased cell proliferation in the SVZ26 and the
recruitment of new neuroblasts into the striatum
after MCAo.27 Other trophic factors, including
hepatocyte growth factor, epidermal growth factor
(EGF), and basic fibroblast growth factor (bFGF)
have been shown to increase the number of BrdUpositive cells in the SVZ and improve endogenous
neurogenesis in the stroke brain.26,28-30
C. Cocaine- and amphetamine-regulated transcript
(CART): CART is an endogenous peptide found in the
brain. The expression of CART can be upregulated by
oxygen–glucose deprivation in culture31 and focal cerebral ischemia or electroconvulsive shock in vivo.32
Treatment with CART before stroke reduces cerebral
infarction in mice.31,33 Recent studies have shown that
intranasal CART treatment from day 3 after MCAo
enhanced neural repair by facilitating endogenous
NPC proliferation and migration from the SVZ, enhancing reinnervation into lesioned cortex, and improving
the functional recovery in stroke animals.9,34 In the
SVZ, CART enhanced immunolabeling of BrdU, the
NPC marker Musashi-1, and the proliferating cell
nuclear antigen, as well as upregulated BDNF mRNA.
In SVZ culture, CART increased the neurosphere formation. CART-mediated cell migration from SVZ
explants was antagonized by anti-BDNF-blocking
antibody. Using 1H-magnetic resonance spectroscopy, increases in N-acetylaspartate levels were
found in the lesioned cortex after CART treatment in
stroke brain. CART also increased the expression of
growth associated protein 43 (GAP43) and FluoroRuby fluorescence in the lesioned cortex. These data
suggest that intranasal CART treatment facilitates
neuroregeneration in the stroke brain.9,34

Naturally Occurring Compounds as Agents
for Enhancing Endogenous Neurogenesis in
Stroke
Dietary supplementation has been shown to stimulate endogenous brain repair mechanisms that afford neuroprotection
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in stroke. Such dietary supplementation at a prestroke period
exerts neuroprotection by reducing inflammation and elevating neurogenesis, thereby prophylactically preparing the
brain in subsequent injury.35,36 The next step is to examine
whether a poststroke dietary treatment is similarly effective
in dampening the secondary cell death associated with
stroke. Many of the components of the diet are naturally
occurring compounds found in daily foods, such as
polyphenols from blueberry and green tea and amino acids
like carnosine, which are high in antioxidants and possess
anti-inflammatory activity that decreases the damaging
effects of reactive oxygen species in the blood, brain, and
other tissues of the body.35,36 Accordingly, developing these
dietary supplements as adjunct agents for the prevention or
treatment of chronic diseases, including the secondary cell
death in stroke, may be clinically relevant. We envision
dietary supplementation as an adjunct therapy for stroke at
acute, subacute, and even chronic periods.

An Overview of Recent Advances in Stroke
Therapeutics
Until now tissue plasminogen activator (tPA) remains the
gold standard treatment for ischemic stroke. Unfortunately,
tPA has a very narrow therapeutic window of 4.5 h poststroke, with its delivery beyond this time frame associated
with serious adverse events, in particular hemorrhagic transformation (HT). Treatment strategies designed to abrogate
the risk of HT and other complications associated with
delayed tPA are likely to improve stroke outcomes. To this
end, drugs that maintain the patency of the cerebrovasculature to avert delayed tPA-induced HT have attracted several
lines of pharmacotherapy-based preclinical research. Noteworthy, among these drugs tested in preclinical stroke models that may confer protection of the cerebrovasculature
include endogenous neurogenesis-enhancing drugs, including those discussed above. 9-12,18-20,23,25,34 Other drugs
examined as potentially exerting anti-HT features include
those that preserve the BBB and those directly enhancing
the brain vasculatures. However, despite encouraging
laboratory evidence demonstrating amelioration of HT in
stroke animals, optimization of the drug regimen, including
the dose, timing, and route of administration, remains to be
determined in order to translate these findings into clinical
applications.

Conclusion
Current drug therapy for stroke is limited by narrow therapeutic windows. Several chemicals, peptides, or trophic
factors have been reported to improve behavioral recovery
when given after stroke.37-39 These drugs mainly target
endogenous repair originated from the neuroprogenitor
cells in the SVZ. This experimental approach may provide
a new potential treatment strategy for stroke patients,
enabling a longer treatment window after the onset of
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stroke, a disorder frequently logistically difficult to treat
immediately after occurrence.
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